About
Orally bioavailable p38alphaMAPK inhibitor
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Clinical Trials (1)
View allTotal Trials
1
As Lead Sponsor
1
As Collaborator
0
Total Enrollment
24
By Phase
PHASE2: 1
By Status
UNKNOWN: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...